# Glycart

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glycart

- Industry: Biotechnology
- Headquarters: Schlieren, Switzerland
- Website: www.roche.com
- Total disclosed funding: $15M
- Latest round: Series A (Nov 26, 2003)
- Investors on record: 7

## About

Glycart is a biotechnology company focused on developing innovative antibody-based therapies to treat various diseases, particularly cancer, through advanced immunotherapy approaches.Founded in 2000 in Schlieren, Switzerland, Glycart specializes in antibody-based therapeutics. In July 2005, Roche acquired Glycart, integrating its innovative technologies into its extensive portfolio. The acquisition was part of Roche's strategy to enhance its capabilities in targeted cancer treatments. The company was co-founded by a group of experts in the field, although specific details about individual founders are not disclosed.Roche is a leading global healthcare company that specializes in pharmaceuticals and diagnostics, offering a comprehensive portfolio of innovative products designed to address significant medical needs. Their core product offerings include targeted therapies, biologics, and diagnostics solutions that focus on the prevention, detection, and treatment of diseases, particularly in areas such as oncology, immunology, infectious diseases, and neuroscience. Roche's flagship products include drugs like Herceptin and Avastin, which are pivotal in cancer treatment, and diagnostic tools such as the cobas series of analyzers that enhance disease detection and management. The company serves a wide range of customers, including healthcare providers, hospitals, and laboratories across various geographical markets, including North America, Europe, and Asia-Pacific regions, ensuring access to their innovative healthcare solutions for patients and healthcare professionals alike.Roche generates revenue primarily through the sale of its pharmaceutical and diagnostic products to healthcare providers, hospitals, and laboratories. The transaction structure typically involves direct sales to these entities or through partnerships with wholesalers and distributors who facilitate product access across different markets. Given that Roche offers both prescription medications and diagnostic solutions, their revenue model encompasses both B2B transactions, supplying hospitals and clinics directly, as well as potential contracts with governmental and private healthcare systems. The company’s revenue is significantly bolstered by its flagship products and ongoing partnerships that focus on advancing research and development within the healthcare sector. Such collaborations may also include licensing agreements with other pharmaceutical companies to expand the reach of their innovative solutions.Glycart, now a part of Roche, will benefit from ongoing research initiatives to develop new antibody-based therapies targeting various cancers. The company plans to leverage Roche’s resources to expand its product pipeline, aiming to launch new immunotherapy treatments in the next few years. The recent acquisition, finalized in July 2005, allows Roche to utilize Glycart's innovative approaches and technologies to enhance its presence in the oncology market, thereby driving future growth opportunities.

## Funding rounds

- Series A, Nov 26, 2003, $15M — Quester Capital Management, Global Life Science Ventures, Novartis Venture Fund, Gilde Healthcare, BioMed Partners, Deutsche Venture Capital, Capital A

## Investors

- Quester Capital Management (https://capitalatlas.ai/funds/quester-capital-management) — Series A
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A
- Deutsche Venture Capital (https://capitalatlas.ai/funds/deutsche-venture-capital) — Series A
- Capital A — Series A